Recently, the Category 1 innovative product Tegileridine Fumarate Injection (Chinese trade name: 艾苏特) of Jiangsu Hengrui Pharmaceuticals Co., Ltd. was approved by China NMPA. It is indicated for moderate to severe pain after abdominal surgery.

　　Tegileridine Fumarate Injection is a complete opioid receptor agonists, which has relative selectivity on μ-opioid receptors (MOR) and is subject to the regulation of narcotic drugs. The marketing of this drug provides new treatment options for patients with moderate to severe pain after abdominal surgery.